Niagen Bioscience Inc reports results for the quarter ended March 31 - Earnings Summary

• Niagen Bioscience Inc NAGE.OQ reported quarterly adjusted earnings of 6 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -1 cents. The mean expectation of four analysts for the quarter was for earnings of 2 cents per share. Wall Street expected results to range from zero cents to 3 cents per share.

• Revenue rose 37.6% to $30.48 million from a year ago; analysts expected $27.10 million.

• Niagen Bioscience Inc's reported EPS for the quarter was 6 cents​.

• The company reported quarterly net income of $5.06 million.

• Niagen Bioscience Inc shares had risen by 26.5% this quarter and gained 64.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Niagen Bioscience Inc is $8.05

This summary was machine generated from LSEG data May 7 at 09:41 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)